PHARMA CITY
Pharma sector: Turnaround for good, 6 small and mid cap pharma stocks with upside potential of up to 32%
While it might not have been making it headline, the pharmaceutical sector or commonly called as pharma has come through a tough period due to US FDA and other factors. It has been witnessing a turnaround of sorts which has been slow but more companies are showing improvement in their performance. Also there is a process of re-rating which is quietly going on in the sector. It was large players which got the attention of tend to gain first and then it is smaller and mid sized. If one looks at the corporate announcement about approval of drugs by the US FDA or other drug regulator or any entry into new markets, a number of them are coming from mid and small companies. Given the lesson which the Indian pharma industry has learnt after its reckless approach between 2005 to 2015, there is a high probability that the sector may gain attention.
Management commentary to set the tone for IT; iffy on city gas cos: Dipan Mehta
The stock market is abuzz with discussions on AI opportunities for IT companies, potential benefits for Maruti from UP discount registration, and challenges faced by city gas distribution companies. Earnings season expectations include stagnant IT earnings but a focus on growth potential with AI. Keep an eye on new listings!
Hot stocks: Brokerage take on L&T Finance, Bajaj Finance, Gujarat Gas, Sun Pharma, and others
Brokerage firms such as UBS have maintained a buy rating on L&T Finance, while JP Morgan maintained an overweight rating on Bajaj Finance, Citi has initiated coverage on Indegene and maintained a sell rating on Gujarat Gas.
Auto stocks: Time for some cool down and also an opportunity? 6 auto stocks with upside potential of upto 28%
It is the sector which has led the rally which the market has witnessed in the last 14 months and rightly so. If one looks at the history, the rallies which are led by the transportation and auto sector are more durable as sales of LCV and certain other auto segments is an indication of the economic situation on the ground. But there is another fact, which is that with a mad rush for stocks a number of them have seen sharp run with valuations moving upward sharply. There is no doubt that the Indian auto sector is going through a transformation and Indian companies are adjusting to it very well. So there is a situation, while the fundamentals are good and improving, valuations have seen a run up. So, there is a likelihood that we might see some cooling off, but that would bring an opportunity for investors who have missed the bus.
QSR chain Charcoal Eats gets ₹45 crore on its plate
The nine-year-old company has 40 doors, mostly cloud kitchens in Mumbai, Pune and Delhi-NCR and competes with Biryani by Kilo and Behrouz Biryani in the ₹6,000 crore biryani segment. For the past several years, biryani has been the most ordered dish on both Swiggy and Zomato, but the market is highly fragmented and unorganised.
Is it a good time to buy travel related stocks? Daljeet Singh Kohli answers
But to assume or extrapolate that this similar kind of execution and similar kind of order book will stay for next three-five years which the stock prices are saying, I think that will be too much of expectation.
- Go To Page 1
Motilal Oswal initiates coverage on Mankind Pharma with target price of Rs 2,650
Motilal Oswal initiated coverage on Mankind Pharma with a 'buy' call and target price of Rs 2,650. The company's disruptive strategy in establishing its DF business has made it an industry leader in prescriptions.
Hot Stocks: Brokerage view on Tata Consumer, Varun Beverages and Mankind Pharma
Top brokerage firms like Motilal Oswal, Jefferies, and Morgan Stanley have issued buy ratings and targets for Mankind Pharma, Nykaa, Tata Consumer, and Varun Beverages.
India, Italy giving boost to Strategic Partnership, enhancing trade, defence and technology ties
Italy, as India's fourth largest trading partner in the EU, has upgraded bilateral relations to a 'Strategic Partnership.' The focus will be on defence, Indo-Pacific, energy, and technology. PM Modi has been invtited for the G7 Summit Outreach. Celebrating 75 years of diplomatic ties, the countries emphasise rule of law, human rights, and inclusive growth. With significant economic engagement and cooperation in science & technology. The nations continue to enhance their strategic partnership.
Jubilant FoodWorks, Glenmark Pharma among 5 stocks with short covering
Short covering refers to the buying of shares in order to close an existing short position or a position that has been sold. Short covering signals a shift in view regarding a security from extreme bearishness to bullishness. In Monday's trading session, five stocks saw top short covering. Here's the list:
Move over PSUs, defensive bets can be the next big story under Modi 3.0
Defensive sectors like FMCG and pharma are emerging as potential winners under Modi 3.0, with experts forecasting gains fueled by rural push and policy actions. Investors are advised to explore stocks like HUL, Dabur, and pharma majors for potential returns amidst PSU valuation concerns.
Mankind Pharma scouts for M&A deals to boost local branded biz
Mankind Pharma, the fourth-largest pharmaceutical company in India, led by Rajeev Juneja, is seeking mergers, acquisitions, and in-licensing deals to enhance its branded formulation business.
As work-from-home trend declines, flexible office spaces work for employees and companies
Providing convenience and flexibility for employees on one hand, cost-effectiveness, and asset-light models for employers on the other, coworking/managed spaces are booming. Demand for such spaces is soaring in large metros and Tier-2 cities alike as companies tighten return-to-office rules.
India has a great story going for it; market levels very sustainable: Prateek Agrawal
We believe over the next month or so as that market tapers off, that bit of selling and the confusion that you see there would also subside.
What should investors do with RIL and ITC? Amnish Aggarwal answers
Elections is a very important event and we are now just I think three trading days away from it. We had issued a note to our clients in which we had identified a few sectors and the scripts which would be doing well irrespective of the outcome of elections.
Sun Pharma shares tumble 5% but brokerages raise target up to Rs 1,785. Should you buy, sell or hold?
In Thursday's trading session on the BSE, shares of Sun Pharmaceutical Industries declined by 5%, reaching the day's low of Rs 1,467. This drop occurred despite the company reporting a 34% year-on-year (YoY) increase in its Q4 profit to Rs 2,654.6 crore, with revenue rising by 10.1% YoY to Rs. 11,813 crore in Q4FY24.
Banking sector is the place to be, don’t be put off by FII selling: Andrew Holland
Andrew Holland, CEO of Avendus Capital Public Markets Alternate Strategies LLP, discusses the impact of FII selling on bank stocks and the upcoming market trends post-elections. Coming to pharma, Holland says the bottom was hit some months back for the whole sector and the prospects are starting to look better not just locally but overseas as well.
Q4 results this week: ITC, ONGC, Sun Pharma, Nykaa, Ircon International and IRFC
ITC, ONGC, IRFC, Ircon International, BHEL, BEL, Sun Pharma, Nykaa, Tata Investment Corporation, Hindalco, Ashok Leyland, and Divi's lab will be releasing their March quarter report cards this week.
Waiting with cash in hand; will invest once election results are out on June 4: Aveek Mitra
Aveek Mitra of Aveksat Financial Advisory strategizes for post-election investments, considering policy changes, Budget implications, and real estate opportunities in the MMR region for long-term growth. Mitra says: "We have built up different scenarios with most likeliest scenarios to the not likeliest scenario and based on that we will immediately try to see that what best we can do with the cash after the 4th June result."
Cold-chain solutions startup Celcius Logistics raises $4.8 million led by IvyCap Ventures
Celcius Logistics connects shippers and transporters and is a solution for all cold-chain requirements, helping with last mile and hyperlocal delivery for all stakeholders.
Banking stocks drive Sensex 111 pts higher from deep red; Nifty above 22,100
Indian equity indices surged, with Sensex and Nifty posting gains. Top gainers included Asian Paints, Sun Pharma, HDFC Bank, TCS, Axis Bank. Tata Motors faced downgrades while Cipla reported a significant profit surge in March 2024.
2 top stock picks from Aditya Arora for near term
The downside levels which I am watching is 21,900 to 21,700. We already achieved 21,900 this morning. So, I think the bottom is almost done. If further correction happens, it could happen till 21,700.
South side story: Can attractive sops turn Chennai into a hub for GCCs?
Can a slew of attractive sops from the state government and a competitive workforce turn Chennai into a hub for GCCs, positioning the state as a healthy alternative to Bengaluru and Hyderabad? In addition to banks and automotive firms, manufacturing, pharma, tech and product companies in the fintech space are considering setting up GCCs in Chennai.
Citi targets clients with a ‘digital nexus’, high transaction volumes
Citi is strategically targeting high transaction volume sectors in India like industrials, auto supply chains, clean energy, mobility, consumer, and healthcare. The bank aims to maintain its lead in funding digital disruptors and supporting startups in navigating market conditions.
Comeback and re-rating supported by numbers? 5 pharma stocks with upside potential of up to 21%
Both at the real business condition and on the valuation cycle on the street. The Indian pharmaceutical sector has undergone significant changes over the past decade. Marking a transition from a period of consolidation and valuation readjustment to one where the focus has shifted towards more sustainable and compliant operational practices. This transformation highlights a shift in the strategic approach adopted by pharmaceutical companies. Historically, the expansion strategies of many pharma companies were driven by optimistic powerpoint presentations forecasting market growth. However, this approach often overlooked the critical aspect of regulatory compliance, leading to various challenges. Over the years the Indian pharmaceutical industry has understood that regulatory compliance might be slightly more time consuming and also expensive but in long run it pays both for the real business growth and improving valuations. Will the industry remember the critical lesson is key.
India becoming attractive for clinical trials, says pharma industry leaders
Over the past decade, India has seen significant improvements in its clinical trial landscape, with a 15-18% growth in phase two and three trials. This growth is attributed to 10 modifications to the Drugs and Cosmetics Act since 2013, aimed at simplifying the process. Despite these advancements, conducting trials in India can still be challenging. Experts note that India's modernizing private hospital networks and improved infrastructure make it an attractive location for trials, with potential for further growth and collaboration in the future.
Stock market update: Nifty Pharma index advances 0.66%
The Nifty Pharma index closed 0.66 per cent up at 18586.2.
Pharma, healthcare see spurt in demand for senior hands as companies prepare for a new future
Pharma and healthcare industries are witnessing growth, driving demand for leadership talent. Companies are seeking expertise in areas like API manufacturing, global market business heads, and CROs. Key roles like CIO, CDO, site head, operations head, sales leaders, and CFOs are in high demand, alongside private equity investments and tech leaders.
Ahead of Market: 10 things that will decide D-Street action on Monday
"We suggest maintaining a positive yet cautious stance as Nifty is set to retest its record high. Needless to say, we need sustainability above 22,150 to end the consolidation and march towards the 22,500+ zone else profit-taking may resume," said Ajit Mishra, Religare Broking.
Load More
